OnKure Therapeutics, Inc. (OKUR)

NGM – Цена в реальном времени. Валюта: USD

3.39

-0.05 (-1.45%)

При закрытии: May 12, 2026, 4:00 PM EDT

3.37

-0.02 (-0.59%)

После закрытия: May 12, 2026, 6:44 PM EDT

05.05.2026

OnKure Therapeutics Reports First Quarter 2026 Financial Results

-- Announced nomination of OKI-355, a next-generation PI3Kα pan-mutant selective inhibitor candidate, in vascular anomalies -- Initiated a discovery research program to expand the company's pipeline in vascular anomalies -- Announced nomination of OKI-345, a next generation PI3Kα pan-mutant selective inhibitor candidate, in breast cancer -- Closed $150 million private placement to advance next-generation PI3Kα pan-mutant programs into clinical development in 2027 -- $192 million cash and cash equivalents as of March 31, 2026, expected to fund operations into 2029 BOULDER, Colo., May 05, 2026 (GLOBE NEWSWIRE) -- OnKure Therapeutics, Inc. (Nasdaq: OKUR), a clinical-stage biopharmaceutical company focused on developing novel precision medicines, today reported financial results for the first quarter ended March 31, 2026, and provided recent business highlights.

27.03.2026

OnKure Therapeutics Announces Oversubscribed $150 Million Private Placement to Advance Next-Generation PI3Kα Pan-Mutant Selective Inhibitor Candidates in Breast Cancer and Vascular Anomalies

-- Financing led by Access Biotechnology with participation from new and existing investors -- Financing to support advancement of two next-generation PI3Kα pan-mutant inhibitors for breast cancer and vascular anomalies – expect to file INDs for each program in 1H 2027 -- Liam Ratcliffe Joins OnKure's Board of Directors BOULDER, Colo., March 27, 2026 (GLOBE NEWSWIRE) -- OnKure Therapeutics, Inc. (Nasdaq: OKUR), a clinical-stage biopharmaceutical company focused on developing novel precision medicines, today announced that it has entered into a securities purchase agreement for a private placement with certain institutional and accredited healthcare investors, raising gross proceeds of approximately $150 million.

12.03.2026

OnKure Therapeutics Reports Fourth Quarter and Full Year 2025 Financial Results

-- Data from the ongoing PIKture-01 trial is expected to be announced in March 2026 ; continued enrollment in breast cancer triplet combinations

06.11.2025

OnKure Therapeutics Reports Third Quarter 2025 Financial Results and Provides a Business Update

-- First patients dosed in triplet expansion arms of the PIKture-01 trial evaluating OKI-219 in combination with fulvestrant and ribociclib, and in combination with trastuzumab and tucatinib in patients with metastatic breast cancer -- Clinical data from OKI-219 PIKture-01 single agent and fulvestrant combination arms are maturing and is now expected to be reported together with initial data from the triplet expansion arms in the first quarter of 2026 -- Significant progress in next-generation PI3Kα pan-mutant inhibitor program; multiple candidates identified - announcement planned for the first quarter of 2026 -- Expansion into Vascular Malformations - additional information to be provided in 2026 BOULDER, Colo., Nov. 06, 2025 (GLOBE NEWSWIRE) -- OnKure Therapeutics, Inc. (Nasdaq: OKUR), a clinical-stage biopharmaceutical company focused on developing novel precision medicines, today reported financial results for the third quarter ended September 30, 2025 and provided a business update.

04.11.2025

OnKure Therapeutics to Participate in Upcoming Investor Conferences

BOULDER, Colo., Nov. 04, 2025 (GLOBE NEWSWIRE) -- OnKure Therapeutics, Inc. (Nasdaq: OKUR), a clinical-stage biopharmaceutical company focused on the development of novel precision medicines, today announced that Nichoals Saccomano, Ph.D., President and Chief Executive Officer, will present and be available for one-on-one investor meetings at the following investor conferences:

Видео

No Data

There is no data to display

Пресс-релизы

05.05.2026

OnKure Therapeutics Reports First Quarter 2026 Financial Results

27.03.2026

OnKure Therapeutics Announces Oversubscribed $150 Million Private Placement to Advance Next-Generation PI3Kα Pan-Mutant Selective Inhibitor Candidates in Breast Cancer and Vascular Anomalies

12.03.2026

OnKure Therapeutics Reports Fourth Quarter and Full Year 2025 Financial Results

-- Data from the ongoing PIKture-01 trial is expected to be announced in March 2026 ; continued enrollment in breast cancer triplet combinations

06.11.2025

OnKure Therapeutics, Inc. (OKUR)

Получите доступ ко всем премиум-функциям лучшего инструмента для анализа акций

Finranks

Компания

Контакты

Мы в соцсетях

OnKure Therapeutics, Inc. (OKUR)

OnKure Therapeutics Reports First Quarter 2026 Financial Results

OnKure Therapeutics Announces Oversubscribed $150 Million Private Placement to Advance Next-Generation PI3Kα Pan-Mutant Selective Inhibitor Candidates in Breast Cancer and Vascular Anomalies

OnKure Therapeutics Reports Fourth Quarter and Full Year 2025 Financial Results

OnKure Therapeutics Reports Third Quarter 2025 Financial Results and Provides a Business Update

OnKure Therapeutics to Participate in Upcoming Investor Conferences

Видео

No Data

Пресс-релизы

OnKure Therapeutics Reports First Quarter 2026 Financial Results

OnKure Therapeutics Announces Oversubscribed $150 Million Private Placement to Advance Next-Generation PI3Kα Pan-Mutant Selective Inhibitor Candidates in Breast Cancer and Vascular Anomalies

OnKure Therapeutics Reports Fourth Quarter and Full Year 2025 Financial Results

OnKure Therapeutics Reports Third Quarter 2025 Financial Results and Provides a Business Update

OnKure Therapeutics Reports First Quarter 2026 Financial Results

OnKure Therapeutics Announces Oversubscribed $150 Million Private Placement to Advance Next-Generation PI3Kα Pan-Mutant Selective Inhibitor Candidates in Breast Cancer and Vascular Anomalies

OnKure Therapeutics Reports Fourth Quarter and Full Year 2025 Financial Results

OnKure Therapeutics Reports Third Quarter 2025 Financial Results and Provides a Business Update

OnKure Therapeutics to Participate in Upcoming Investor Conferences

Видео

No Data

Пресс-релизы

OnKure Therapeutics Reports First Quarter 2026 Financial Results

OnKure Therapeutics Announces Oversubscribed $150 Million Private Placement to Advance Next-Generation PI3Kα Pan-Mutant Selective Inhibitor Candidates in Breast Cancer and Vascular Anomalies

OnKure Therapeutics Reports Fourth Quarter and Full Year 2025 Financial Results

OnKure Therapeutics Reports Third Quarter 2025 Financial Results and Provides a Business Update

Search stocks

OnKure Therapeutics, Inc. (OKUR)

Получите доступ ко всем премиум-функциям лучшего инструмента для анализа акций

Finranks

Компания

Контакты

Мы в соцсетях

OnKure Therapeutics, Inc. (OKUR)

OnKure Therapeutics Reports First Quarter 2026 Financial Results

OnKure Therapeutics Announces Oversubscribed $150 Million Private Placement to Advance Next-Generation PI3Kα Pan-Mutant Selective Inhibitor Candidates in Breast Cancer and Vascular Anomalies

OnKure Therapeutics Reports Fourth Quarter and Full Year 2025 Financial Results

OnKure Therapeutics Reports Third Quarter 2025 Financial Results and Provides a Business Update

OnKure Therapeutics to Participate in Upcoming Investor Conferences

Видео

No Data

Пресс-релизы

OnKure Therapeutics Reports First Quarter 2026 Financial Results

OnKure Therapeutics Announces Oversubscribed $150 Million Private Placement to Advance Next-Generation PI3Kα Pan-Mutant Selective Inhibitor Candidates in Breast Cancer and Vascular Anomalies

OnKure Therapeutics Reports Fourth Quarter and Full Year 2025 Financial Results

OnKure Therapeutics Reports Third Quarter 2025 Financial Results and Provides a Business Update

OnKure Therapeutics Reports First Quarter 2026 Financial Results

OnKure Therapeutics Announces Oversubscribed $150 Million Private Placement to Advance Next-Generation PI3Kα Pan-Mutant Selective Inhibitor Candidates in Breast Cancer and Vascular Anomalies

OnKure Therapeutics Reports Fourth Quarter and Full Year 2025 Financial Results

OnKure Therapeutics Reports Third Quarter 2025 Financial Results and Provides a Business Update

OnKure Therapeutics to Participate in Upcoming Investor Conferences

Видео

No Data

Пресс-релизы

OnKure Therapeutics Reports First Quarter 2026 Financial Results

OnKure Therapeutics Announces Oversubscribed $150 Million Private Placement to Advance Next-Generation PI3Kα Pan-Mutant Selective Inhibitor Candidates in Breast Cancer and Vascular Anomalies

OnKure Therapeutics Reports Fourth Quarter and Full Year 2025 Financial Results

OnKure Therapeutics Reports Third Quarter 2025 Financial Results and Provides a Business Update